The Oncology Institute, Inc. (NASDAQ:TOI) Shares Acquired by Kent Lake Capital LLC

Kent Lake Capital LLC raised its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 492.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,085,171 shares of the company's stock after buying an additional 901,956 shares during the quarter. Kent Lake Capital LLC owned about 1.47% of Oncology Institute worth $2,214,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of TOI. Josh Arnold Investment Consultant LLC grew its holdings in shares of Oncology Institute by 77.4% in the third quarter. Josh Arnold Investment Consultant LLC now owns 1,877,472 shares of the company's stock valued at $2,647,000 after purchasing an additional 819,321 shares during the period. Balyasny Asset Management L.P. grew its holdings in shares of Oncology Institute by 186.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,253,037 shares of the company's stock valued at $2,556,000 after purchasing an additional 815,458 shares during the period. BlackRock Inc. grew its holdings in shares of Oncology Institute by 101.8% in the third quarter. BlackRock Inc. now owns 1,529,650 shares of the company's stock valued at $7,083,000 after purchasing an additional 771,555 shares during the period. Cincinnati Insurance Co. purchased a new stake in shares of Oncology Institute in the fourth quarter valued at about $1,427,000. Finally, Tiff Advisory Services LLC purchased a new stake in shares of Oncology Institute in the third quarter valued at about $593,000. Hedge funds and other institutional investors own 36.86% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group began coverage on shares of Oncology Institute in a research note on Monday, February 26th. They set a "buy" rating and a $2.50 target price for the company.

Insiders Place Their Bets

In other Oncology Institute news, major shareholder Havencrest Healthcare Partners sold 11,986 shares of the stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $2.13, for a total transaction of $25,530.18. Following the completion of the transaction, the insider now owns 68,014 shares of the company's stock, valued at $144,869.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 62,780 shares of company stock valued at $137,838 over the last 90 days. 13.10% of the stock is owned by company insiders.

Oncology Institute Price Performance

TOI stock remained flat at $1.50 during mid-day trading on Friday. 76,944 shares of the company's stock traded hands, compared to its average volume of 145,840. The company has a quick ratio of 4.34, a current ratio of 4.71 and a debt-to-equity ratio of 1.19. The stock has a market capitalization of $110.63 million, a price-to-earnings ratio of -1.63 and a beta of 0.68. The firm's 50-day simple moving average is $1.79 and its two-hundred day simple moving average is $1.79. The Oncology Institute, Inc. has a one year low of $0.33 and a one year high of $2.66.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services.